Last reviewed · How we verify

NCT04470882

Use of Safety Behaviors in Exposure Therapy for Arachnophobia

Completed NA Last updated 18 October 2021
What this trial tests

NA trial testing Exposure with faded safety behaviors in Specific Phobia in 59 participants. Completed in 6 April 2020.

Timeline
28 February 2019
Primary endpoint
6 April 2020
6 April 2020

Quick facts

Lead sponsorUniversity of Nevada, Reno
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment59
Start date28 February 2019
Primary completion6 April 2020
Estimated completion6 April 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Nevada, Reno

Who can join

18 and older, any sex, with Specific Phobia or Arachnophobia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study examines the impact of safety behaviors (i.e., unnecessary protective actions) on outcomes of exposure therapy for spider phobia. Researchers will compare exposure therapy with (a) no safety behaviors, (b) safety behaviors faded toward the end of treatment, and (c) unfaded safety behaviors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Specific Phobia

Currently open trials in the same condition.

Other University of Nevada, Reno trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04470882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing